The nation of Zimbabwe has declined a significant US healthcare agreement worth $367m (£272m) spanning five years over the United States' demand for confidential biological samples.
This move became public following a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesperson has since clarified that the US was seeking biological samples for scientific study and commercial gain but refused to share the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued dialogue to reach a deal agreeable to both sides so the nation's vital HIV programme can continue.
Broader Background
This rejection comes after a similar case in Kenya, where a court halted a related deal with the US following legal challenges were filed about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump claimed its spending was "wasteful" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
Based on statements, Sixteen African countries have to date signed similar health pacts, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to share its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for scientific discovery with no assurance that the end products would be available to our citizens if a future disease outbreak arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining frameworks already set up through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This mechanism is designed to guarantee that when a nation contributes its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how subsequent co-operation might be designed in a manner that respects the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but recommended that negotiations should continue considering much of the country's Aids initiatives were funded by foreign aid.
"Where specific concerns exist, including those involving data governance or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," it said.
The halted deal highlights the complex debate between receiving crucial foreign assistance and safeguarding local interests in an ever more data-driven world.